Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
455.3 USD +2.77% Intraday chart for Vertex Pharmaceuticals Incorporated -0.35% +11.91%
May. 31 BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
May. 31 Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 56,303 61,457 55,834 74,127 104,849 117,502 - -
Enterprise Value (EV) 1 52,495 54,798 48,309 63,349 93,630 103,528 98,910 93,785
P/E ratio 48.5 x 23 x 24.4 x 22.5 x 29.3 x 30 x 26.8 x 23.6 x
Yield - - - - - - - -
Capitalization / Revenue 13.5 x 9.9 x 7.37 x 8.3 x 10.6 x 10.9 x 10.1 x 9.15 x
EV / Revenue 12.6 x 8.83 x 6.38 x 7.09 x 9.49 x 9.63 x 8.47 x 7.31 x
EV / EBITDA 27.7 x 15.2 x 10.8 x 12.8 x 20.6 x 19.3 x 16.9 x 14.3 x
EV / FCF 35.1 x 18.3 x 20.1 x 16.1 x 28.1 x 23.9 x 20.7 x 16.7 x
FCF Yield 2.85% 5.46% 4.99% 6.2% 3.56% 4.18% 4.84% 5.98%
Price to Book 9.38 x 7.07 x 5.53 x 5.33 x 5.96 x 5.46 x 4.7 x 4.08 x
Nbr of stocks (in thousands) 257,150 260,038 254,252 256,691 257,683 258,053 - -
Reference price 2 219.0 236.3 219.6 288.8 406.9 455.3 455.3 455.3
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,163 6,206 7,574 8,931 9,869 10,753 11,672 12,837
EBITDA 1 1,893 3,601 4,470 4,941 4,556 5,374 5,840 6,576
EBIT 1 1,786 3,491 4,344 4,793 4,375 5,054 5,436 6,216
Operating Margin 42.9% 56.25% 57.35% 53.67% 44.33% 47% 46.57% 48.42%
Earnings before Tax (EBT) 1 1,395 3,117 2,730 4,232 4,380 4,857 5,519 6,413
Net income 1 1,177 2,712 2,342 3,322 3,620 3,980 4,441 5,094
Net margin 28.27% 43.7% 30.92% 37.2% 36.68% 37.01% 38.05% 39.69%
EPS 2 4.510 10.29 9.010 12.82 13.89 15.16 16.99 19.31
Free Cash Flow 1 1,494 2,994 2,408 3,925 3,337 4,325 4,786 5,605
FCF margin 35.89% 48.24% 31.8% 43.95% 33.81% 40.22% 41% 43.66%
FCF Conversion (EBITDA) 78.92% 83.15% 53.89% 79.44% 73.24% 80.48% 81.94% 85.24%
FCF Conversion (Net income) 126.94% 110.4% 102.84% 118.16% 92.19% 108.66% 107.76% 110.03%
Dividend per Share 2 - - - - - - - -
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 2,073 2,098 2,196 2,334 2,303 2,375 2,493 2,484 2,518 2,691 2,662 2,689 2,734 2,695 2,774
EBITDA 1 - - - - - - - 1,215 1,210 1,390 1,310 1,269 1,243 - -
EBIT 1 1,124 1,166 1,187 1,289 1,150 902.3 1,148 1,173 1,151 1,336 1,252 1,235 1,228 1,310 1,402
Operating Margin 54.23% 55.61% 54.05% 55.24% 49.95% 37.99% 46.04% 47.24% 45.73% 49.67% 47.02% 45.93% 44.94% 48.63% 50.54%
Earnings before Tax (EBT) 1 870.9 954.8 1,024 1,176 1,077 891.5 1,162 1,179 1,148 1,279 1,210 1,186 1,190 1,227 1,317
Net income 1 770.1 762.1 810.5 930.5 818.9 699.8 915.7 1,035 968.8 1,100 982.4 948.5 929.1 969.4 1,041
Net margin 37.16% 36.33% 36.9% 39.86% 35.56% 29.47% 36.73% 41.69% 38.48% 40.87% 36.91% 35.27% 33.99% 35.98% 37.51%
EPS 2 3.000 2.960 3.130 3.590 3.150 2.690 3.520 3.970 3.710 4.210 3.753 3.629 3.564 3.670 3.930
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 1/26/22 5/5/22 8/4/22 10/27/22 2/7/23 5/1/23 8/1/23 11/6/23 2/5/24 5/6/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 3,808 6,659 7,525 10,779 11,218 13,974 18,592 23,717
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,494 2,994 2,409 3,925 3,337 4,325 4,786 5,605
ROE (net income / shareholders' equity) 22.4% 36.7% 36% 32.1% 23% 22.4% 19.5% 19.4%
ROA (Net income/ Total Assets) 16.2% 27% 18.8% 21% 17.7% 15.3% 13.7% 13%
Assets 1 7,282 10,035 12,433 15,792 20,441 25,954 32,440 39,245
Book Value Per Share 2 23.30 33.40 39.70 54.10 68.20 83.40 96.90 112.0
Cash Flow per Share 2 6.020 12.40 10.20 15.90 13.60 18.80 19.10 20.30
Capex 1 75.5 260 235 205 200 214 223 226
Capex / Sales 1.81% 4.19% 3.1% 2.29% 2.03% 1.99% 1.91% 1.76%
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3 USD
Average target price
463.5 USD
Spread / Average Target
+1.80%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
INSMED INCORPORATED Stock Insmed Incorporated
+77.64% 8.87B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. Financials Vertex Pharmaceuticals Incorporated